Home/Capabilities/Regulatory excellence/CMC and quality
Regulatory excellence
CMC and quality
The part of the dossier that never stops changing, and the part where avoidable delay most often originates.
Why it matters
Most avoidable delay originates in the quality dossier
Clinical questions are usually anticipated. Quality questions are usually not — and they arrive as major objections that stop the clock while a stability study runs or a specification is rejustified.
CMC is where a development programme's earlier compromises become visible. A specification set to accommodate an early process, a comparability position never properly closed, a starting material justification that worked for one market and not another — each is manageable at the time and expensive at submission.
Quality is also the part of the dossier that never stops changing. Sites move, suppliers change, processes are optimised, and each change has to be classified, justified and filed in every market where the product is registered.
The quality dossier
Module 3, and the summaries that carry it
Assessors read the Quality Overall Summary before they read Module 3. A strong dossier with a weak summary generates questions that a strong summary would have prevented.
Drug substance
Manufacture, characterisation, control of materials, process controls, impurity and elemental impurity strategy, container closure and stability.
Drug product
Formulation development and rationale, manufacture and process validation approach, excipient control, specification and analytical procedures.
Specifications and justification
Setting limits that are defensible against clinical and stability data rather than against convenience, and holding them consistent across markets.
Analytical procedures
Validation and transfer documentation, and the lifecycle position when methods are subsequently improved.
Stability
Study design, bracketing and matrixing where justified, shelf-life proposals, and the extrapolation position that supports them.
Comparability
Assessment and documentation where a process, site or scale changes — the area that most often determines whether a change is minor or major.
Post-approval
Change is the normal state, not the exception
A commercial product will accumulate dozens of CMC changes over its life. Whether that is routine or disruptive depends almost entirely on how well the changes are classified and planned.
The recurring failure is treating each change as an isolated regulatory task. A site transfer, a supplier change and a specification update filed separately across forty markets is an enormous amount of work; the same three changes assessed together, grouped where the framework allows and sequenced deliberately, is a fraction of it.
Getting there requires the classification decision to be made properly and early — before manufacturing has committed to a date that regulatory cannot meet.
What we do
How we work on CMC
Read the dossier as an assessor would
A gap assessment against what a reviewer will look for, not against a completeness checklist.
Close the justification gaps
Author or rework the sections where the data exists but the argument connecting it to the claim does not.
Classify change properly
Determine the regulatory impact of a proposed change in every affected market before commitments are made.
Plan comparability early
Design the comparability package when the change is designed, not once the change has already been made.
Prepare for questions
Identify the likely objection areas and prepare positions before the questions arrive, not during the clock stop.
Bring us the challenge
Where are you in this, right now?
The most useful conversations start with the specific decision or deadline in front of you, not with a service category.